Beneficial Ownership Report · SCHEDULE 13G
AEON Biopharma, Inc.
AEONNYSE_AMERICANEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- AEON Biopharma, Inc.
- Company CIK
- 0001837607
- Street
- 130 VANTIS DRIVE
- Street (continued)
- SUITE 170
- City
- ALISO VIEJO
- State / country code
- CA
- Postal code
- 92656
Statement details
- Security class
- Class A common stock, $0.0001 par value per share
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- Nantahala Capital Management, LLC
- Citizenship / organization
- MA
- Reporting person type
- IA
- Aggregate amount owned
- 5,048,027.00
- Percent of class
- 9.99
- Sole voting power
- 0.00
- Shared voting power
- 5,048,027.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 5,048,027.00
- Aggregate excludes certain shares
- N
Reporting person 2
- Name
- Wilmot B. Harkey
- Citizenship / organization
- X1
- Reporting person type
- HC
- Aggregate amount owned
- 5,048,027.00
- Percent of class
- 9.99
- Sole voting power
- 0.00
- Shared voting power
- 5,048,027.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 5,048,027.00
- Aggregate excludes certain shares
- N
Reporting person 3
- Name
- Daniel Mack
- Citizenship / organization
- X1
- Reporting person type
- HC
- Aggregate amount owned
- 5,048,027.00
- Percent of class
- 9.99
- Sole voting power
- 0.00
- Shared voting power
- 5,048,027.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 5,048,027.00
- Aggregate excludes certain shares
- N
Item 1
Issuer
AEON Biopharma, Inc.
Principal executive office address
130 VANTIS DRIVE SUITE 170 ALISO VIEJO, CALIFORNIA, 92656
Item 2
Citizenship
(1) Nantahala is a Massachusetts limited liability company. (2) Each of Messrs. Harkey and Mack is a citizen of the United States of America.
Filing person
(1) Nantahala Capital Management, LLC ("Nantahala") (2) Wilmot B. Harkey (3) Daniel Mack (together the "Reporting Persons")
Principal business or residence address
130 Main St. 2nd Floor, New Canaan, Connecticut 06840
Item 3
Not applicable indication
N
Type of filing person
IA · HC
Item 4
Percent of class
As of September 30, 2026, each of the Reporting Persons may be deemed to be the beneficial owner of the following percentage of the total number of Shares outstanding: (1) Nantahala Capital Management, LLC ("Nantahala") : 9.99% (2) Wilmot B. Harkey: 9.99% (3) Daniel Mack: 9.99%
Amount beneficially owned
As of September 30, 2026, Nantahala may be deemed to be the beneficial owner of 5,048,027 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares. The 5048027 Shares Include 648027 Shares which may be acquired by the Reporting Persons within sixty days through the exercise of convertible securities.
Sole voting power
(1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.
Shared voting power
(1) Nantahala Capital Management, LLC ("Nantahala") : 5,048,027 Shares. (2) Wilmot B. Harkey: 5,048,027 Shares. (3) Daniel Mack: 5,048,027 Shares.
Sole dispositive power
(1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.
Shared dispositive power
(1) Nantahala Capital Management, LLC ("Nantahala") : 5,048,027 Shares. (2) Wilmot B. Harkey: 5,048,027 Shares. (3) Daniel Mack: 5,048,027 Shares.
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
N
Ownership on behalf of another person
BLACKWELL PARTNERS LLC - SERIES A, a fund advised by Nantahala, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of more than five percent of the outstanding shares of common stock beneficially owned by Nantahala reported herein.
Item 7
Not applicable indication
N
Subsidiaries
Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in ss. 240.13d-1(b)(1)(ii)(E). See Item 4(a).
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Exhibit 24 - Power of Attorney incorporated by reference to the November 13, 2026 filing. https://www.sec.gov/Archives/edgar/data/1502725/000110465926127115/0001104659-26-127115-index.htm.
Signature 1
- Reporting person
- Nantahala Capital Management, LLC
- Signed
- /s/ Taki Vasilakis
- Title
- Taki Vasilakis / Chief Compliance Officer
- Date
- 11/13/2026
Signature 2
- Reporting person
- Wilmot B. Harkey
- Signed
- /s/ Taki Vasilakis, attorney-in-fact for
- Title
- Wilmot B. Harkey
- Date
- 11/13/2026
Signature 3
- Reporting person
- Daniel Mack
- Signed
- /s/ Taki Vasilakis, attorney-in-fact for
- Title
- Daniel Mack
- Date
- 11/13/2026
Company context
AEON Biopharma is a biopharmaceutical company pursuing full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX®. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau®. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and the European Medicines Agency for the manufacture of certain third-party botulinum toxin products. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.